Drug Trial Radar · NCT07704866
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Aug 31, 2028
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- FutureGen Biopharmaceutical (Beijing) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors that are positive for Claudin 18.2 and have progressed on, are intolerant to, or lack standard therapy. The Phase I dose-escalation part (using a BF-BOIN design) assesses safety, tolerability, and pharmacokinetics, and determines the recommended Phase II dose (RP2D) of FG-B901 when given with fixed-dose FG-M108. The Phase IIa expansion cohorts, grouped by tumor type, further evaluate safety and preliminary efficacy, with antitumor activity measured by RECIST 1.1 and iRECIST, while also exploring biomarker correlates. Key eligibility requires CLDN18.2 positivity (≥10% tumor cells with ≥1+ membrane staining by IHC), ECOG performance status 0-1, and measurable disease. Up to approximately 30 participants will be enrolled per cohort in Phase IIa. The study aims to provide initial evidence on the combination's safety, tolerability, PK, immunogenicity, and clinical activity in this hard-to-treat population.
Conditions
- Claudin 18.2
- Solid Tumor Malignancies
Interventions
FG-B901Drug
Accelerated titration method, IV infusion Q3W; Adaptive BOIN design, IV infusion Q3W. (21-day cycles)
FG-B901Drug
1\~2 dose levels of FG-B901 will be tested according to an accelerated titration method followed by a adaptive BOIN design
FG-M108Drug
300 mg/m2, IV infusion Q3W (21-day cycles)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety assessed by Adverse Events (AEs)Time frame: Up to 24 months
- Objective Response Rate (ORR)Time frame: Up to 24 months
- Disease control rate (DCR)Time frame: Up to 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Ha’erbin, China
The First Hospital of China Medical University
Shenyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.